An Open-label Pilot Study Using Carvedilol-CR as a P-glycoprotein Inhibitor as Adjunct Therapy in the Treatment of Medically-refractory Epilepsy
Latest Information Update: 10 Aug 2022
At a glance
- Drugs Carvedilol (Primary)
- Indications Epilepsy
- Focus Therapeutic Use
- 13 Apr 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov
- 25 Apr 2011 Planned end date changed from 1 Dec 2010 to 1 Apr 2011 as reported by ClinicalTrials.gov.
- 25 Apr 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.